SELECT * FROM `stock_list` WHERE `symbol` = "IGC" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 SELECT * FROM `stock_list` where symbol='IGC' AND exchange = 'AMEX' limit 0,1 SELECT * FROM `stock_list` WHERE `symbol` = "IGC" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
IGC (IGC Pharma) Selling, General, & Admin. Expense
What is IGC Pharma Selling, General, & Admin. Expense?
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. IGC Pharma's selling, general, & admin. expense for the
three
months ended in Dec. 2023 was $2.23 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was $8.88 Mil.
IGC Pharma Selling, General, & Admin. Expense Historical Data
The historical data trend for IGC Pharma's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
IGC Pharma Selling, General, & Admin. Expense Chart
Competitive Comparison of IGC Pharma's Selling, General, & Admin. Expense
For the Biotechnology subindustry, IGC Pharma's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Selling, General, & Admin. Expense falls into.
IGC Pharma Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (AMEX:IGC) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
IGC Pharma Selling, General, & Admin. Expense Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your 